



Evofem Biosciences to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference

SAN DIEGO, Dec. 21, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference.

Evofem's CEO, Sandra Pelletier, will provide updates on the commercialization of [Phexxi® \(lactic acid, citric acid and potassium bitartrate\)](#), the first and only FDA-approved, hormone free contraceptive vaginal gel, and the pivotal Phase 3 [EVOGUARD](#) trial, which is evaluating EVO100 for the prevention of chlamydia and gonorrhea in women and currently enrolling subjects at study centers across the U.S.

The presentation will be available for on-demand listening beginning Monday, January 11, 2021, at 6:00 AM Eastern Time on the Investors section of the Evofem Biosciences website at www.evofem.com, under the [Events and Presentations](#) tab.

About Evofem Biosciences

Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, [Phexxi® \(lactic acid, citric acid and potassium bitartrate\)](#), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is evaluating EVO100 in a Phase 3 clinical trial, '[EVOGUARD](#),' for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. For more information, please visit www.evofem.com.

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact

Amy Raskopf

Evoform Biosciences, Inc.

araskopf@evofem.com

Mobile: (917) 673-5775

Media Contact

Ellen Thomas

Evoform Biosciences, Inc.

ethomas@evofem.com

Mobile: (718) 490-3248

SOURCE Evoform Biosciences, Inc.